Biomea Fusion (BMEA) director receives 173,711-share stock option grant at $1.15

Rhea-AI Filing Summary

Biomea Fusion, Inc. director Julianne Averill reported receiving a stock option grant under the company’s equity plan. The option covers 173,711 shares of Common Stock at an exercise price of $1.15 per share and expires on June 9, 2036.

The filing states this is a compensation-related award, not an open-market purchase or sale. According to the vesting terms, all underlying shares will vest in full on the earlier of one year from the grant date or immediately before the next annual stockholder meeting, provided she continues serving the company through that date.

Insights

Equity Compensation Analyst

Director receives time-based stock option grant as routine compensation.

The filing shows director Julianne Averill receiving an option to acquire 173,711 shares at $1.15 per share, expiring in 2036. The transaction is coded as a grant, indicating standard equity compensation rather than a market trade.

The option vests in full after one year or just before the next annual stockholder meeting, subject to continued service. Because this is a single grant with no sales or exercises and no trading plan reference, it appears to be a routine incentive award, not a directional signal about the stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Averill Julianne

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	173,711	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 173,711 shares (Direct)

Footnotes (1)

1. F1. The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Key Figures

Option grant size: 173,711 shares Exercise price: $1.15 per share Expiration date: June 9, 2036 +2 more

5 metrics

Option grant size 173,711 shares Stock Option (Right to Buy) granted to director

Exercise price $1.15 per share Conversion or exercise price of stock option

Expiration date June 9, 2036 Option expiration for director grant

Underlying shares 173,711 shares Common Stock underlying the option

Derivative holdings after grant 173,711 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), underlying security, exercise price, vest in full, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

underlying security financial

"underlying_security_title: "Common Stock" defines the underlying security"

exercise price financial

"conversion_or_exercise_price of 1.1500 per share is the exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"The shares underlying the stock option will vest in full upon the earlier of..."

annual meeting of the Issuer's stockholders financial

"immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 04:15 PM Accepted by SEC EDGAR 06/12/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What did Biomea Fusion (BMEA) director Julianne Averill report in this Form 4?

Director Julianne Averill reported receiving a stock option grant for 173,711 shares of Biomea Fusion common stock. The option is compensation-related, not a market trade, and gives her the right to buy shares at a fixed exercise price of $1.15 per share until June 9, 2036.

How many Biomea Fusion (BMEA) shares are covered by the new stock option?

The stock option granted to director Julianne Averill covers 173,711 shares of Biomea Fusion common stock. These shares are not issued immediately; they become purchasable upon vesting and exercise of the option at the specified $1.15 per-share exercise price before the 2036 expiration date.

What is the exercise price and expiration date of the Biomea Fusion (BMEA) option grant?

The option has an exercise price of $1.15 per share and expires on June 9, 2036. This means the director can choose to buy up to 173,711 shares at $1.15 any time after vesting and before expiration, subject to the plan’s terms and conditions.

When do the Biomea Fusion (BMEA) director stock options vest?

The underlying shares vest in full on the earlier of one year from the grant date or immediately before the next annual stockholder meeting. Vesting is conditioned on the director’s continued service with Biomea Fusion through that vesting date, according to the Form 4 footnote disclosure.

Does this Biomea Fusion (BMEA) Form 4 show any stock being bought or sold on the market?

No, the Form 4 reports a grant of stock options as compensation, not an open-market buy or sell. The transaction code is “A” for award, and the transaction price is shown as zero because no cash changed hands at grant, only the right to buy later at $1.15 per share.

How does this Biomea Fusion (BMEA) option grant affect the director’s holdings?

After the transaction, the Form 4 shows 173,711 derivative securities (stock options) held by the director. These options represent potential future ownership if exercised, but they are separate from any existing common shares and depend on vesting and the director choosing to exercise them.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Averill Julianne

(Last) (First) (Middle)

C/O BIOMEA FUSION, INC.

1599 INDUSTRIAL ROAD

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Biomea Fusion, Inc. [ BMEA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.15	06/10/2026		A		173,711		(1)	06/09/2036	Common Stock	173,711	$0	173,711	D

Explanation of Responses:

1. The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

	/s/ Rainer Erdtmann as Attorney-in-Fact for Julianne Averill	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)